---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-081882"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2024-07-23T23:59:59+00:00"
generated_at: "2026-05-31T18:01:55.130557+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Verastem initiates rolling NDA for avutometinib/defactinib; RAMP 201 median duration 9 months

## Summary
- Rolling NDA for avutometinib+defactinib in recurrent KRAS mutant LGSOC started May 2024; priority review requested.
- RAMP 201 interim data (Feb 2024 cutoff): median duration 9 months; KRAS mt 14 months, KRAS wt 7 months; 31/58 KRAS mt still on treatment.
- Estimated addressable market: annual ~$300M KRAS mt, ~$270M KRAS wt; prevalent ~$1.7B KRAS mt, ~$1.1B KRAS wt based on $34k/month cost.
- GenFleet collaboration: IND cleared June 2024, first patient dosed in China Phase 1/2 for KRAS G12D inhibitor GFH375/VS-7375.

## SEC filing metadata
- accession: 0001104659-24-081882
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2024-07-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465924081882/0001104659-24-081882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465924081882/tm2413643d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-081882
- JSON: https://secwatch.observer/filing/0001104659-24-081882.json
- Plain text: https://secwatch.observer/filing/0001104659-24-081882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.